Molecular Vision: Kang, Mol Vis 2011; 17:2544-2551. Table 2

Table 2. Effect modification by female reproductive attributes on the associations of selected NOS3 polymorphisms and POAG.

SNP	Genotype	Overall association between SNP genotypes and POAG		Menarche <13 years	Menarche ≥13 years		Parous 3+ children	Parous 1–2 children		No oral contraceptive use	Oral contraceptive use
		RR (95% CI)	Number of Cases (MEN-/ MEN+)‡	RR (95% CI)§	RR (95% CI)§	Number of cases (PAR3+/ PAR3-)‡	RR (95% CI)§	RR (95% CI)§	Number of cases (OC-/ OC+)‡	RR (95% CI)§	RR (95% CI)§
Promoter −786C/T	TT	1.00 (ref)	67/70	1.00	0.91 (0.59, 1.41)	46/25	1.00	1.20 (0.58, 2.49)	78/59	1.00	1.60 (1.01, 2.55)
	TC	1.11 (0.83, 1.47)	86/80	1.24 (0.82, 1.88)	0.95 (0.62, 1.44)	56/25	0.92(0.54, 1.58)	1.19(0.60, 2.35)	95/71	1.22 (0.84, 1.78)	1.62 (1.04, 2.51)
	CC	1.17 (0.81, 1.70)	34/28	1.33 (0.78, 2.27)	0.99 (0.57, 1.71)	25/7	1.32 (0.67, 2.63)	0.46 (0.15, 1.40)	36/26	1.38 (0.85, 2.27)	1.56 (0.87, 2.81)
					p-int=0.54			p-int=0.13			p-int=0.35
Glu298Asp (rs1799983)	GG	1.00 (ref)	79/85	1.00	1.20 (0.80, 1.81)	49/34	1.00	2.03(1.07, 3.83)	90/74	1.00	1.35 (0.89, 2.04)
	GT	0.98 (0.74, 1.31)	78/65	1.50 (0.99, 2.27)	0.90 (0.59, 1.36)	56/19	1.41 (0.83, 2.41)	1.18 (0.57, 2.44)	89/54	1.16 (0.80, 1.71)	1.22 (0.77, 1.93)
	TT	1.45 (0.98, 2.13)	30/26	2.13 (1.20, 3.77)	1.45 (0.81, 2.59)	19/4	2.01 (0.96, 4.20)	0.51 (0.15, 1.78)	29/27	1.32 (0.78, 2.24)	2.87 (1.50, 5.52)
					p-int=0.05			p-int=0.003¶			p-int=0.60
rs3918188	CC	1.00 (ref)	100/73	1.00	0.54 (0.36, 0.81)	61/19	1.00	0.66 (0.33, 1.32)	98/75	1.00	1.22 (0.80, 1.84)
	CA	0.79 (0.60, 1.03)	73/84	0.57 (0.39, 0.85)	0.56 (0.39, 0.83)	55/30	0.91 (0.54, 1.52)	1.23 (0.67, 2.26)	91/66	0.74 (0.52, 1.06)	0.99 (0.66, 1.48)
	AA	0.69 (0.46, 1.05)	16/25	0.31 (0.16, 0.59)	0.71 (0.40, 1.26)	11/9	0.56 (0.24, 1.33)	1.42 (0.50, 4.01)	24/17	0.59 (0.34, 1.03)	0.90 (0.47, 1.73)
					p-int=0.0007¶			p-int=0.04			p-int=0.59
rs7830	CC	1.00 (ref)	88/84	1.00	0.83 (0.56, 1.23)	54/29	1.00	1.36 (0.70, 2.61)	101/71	1.00	1.22 (0.80, 1.86)
	CA	0.75 (0.57, 0.98)	75/71	0.76 (0.51, 1.14)	0.58 (0.39, 0.86)	52/22	0.73 (0.45, 1.21)	0.75 (0.39, 1.45)	79/67	0.69 (0.48, 0.99)	0.99 (0.66, 1.49)
	AA	1.16 (0.78, 1.73)	27/28	1.04 (0.58, 1.86)	1.09 (0.62, 1.92)	21/7	1.23 (0.59, 2.56)	0.93 (0.32, 2.68)	34/21	1.16 (0.70, 1.93)	1.44 (0.75, 2.75)
					p-int=0.82			p-int=0.29			p-int=0.86

Abbreviations: POAG: primary-open angle glaucoma; OC+: oral contraceptive use, OC-: never used OC; PAR3+: parous with 3 or more children, PAR3-: parous with 1 or 2 children; MEN-: menarche<13, MEN+: menarche≥13. ‡The number of cases may not add up to 374 because those with missing data were not included in analyses. §Adjusted for family history of glaucoma, hypertension, diabetes, parity, oral contraceptive use, smoking status, body mass index, age at menopause, postmenopausal hormone use, alcohol intake, caffeine intake, physical activity. Statistically significant with multiple testing correction (False Discovery Rate).